SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)
ACAD 25.04+0.9%Nov 28 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (273)4/19/2006 3:10:10 PM
From: keokalani'nui   of 588
 
I read somewhere fda may be asking for 3 year safety data on fty720 in MS, which would be at least a year longer than EU, and nvs is seriously thinking about delivering a vertical prestidigitation. Would be tragic, the drug looks good.

(But it would be, I suppose, the right thing if CB1 accounted for its MS benefit, if its purported MoA of leukocyte sequestration was in fact a causative risk for PML.)

Maybe this also accounts for excitement? Reaching, I know. Hard to believe 720's effects are due to much more than efect on immune system.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News